路新磊,韩雅玲,王效增,荆全民,李毅,鄢高亮,李晶,徐波

• 1:中国人民解放军沈阳军区总医院心内科
• 2:北京市阜外心血管病医院心内科

摘要(Abstract)：

目的评估国产生物可降解涂层雷帕霉素洗脱支架(ExcelTM,山东吉威医疗制品有限公司)治疗冠状动脉小血管病变的长期临床安全性与有效性。方法 2006年6月至11月在4个国家(中国、印度尼西亚、马来西亚、泰国)的59个中心共有2077例接受单一ExcelTM支架治疗的患者连续入选CREATE研究。以靶病变两端参考血管直径≤2.75mm作为小血管标准(有一支靶血管直径≤2.75mm即为小血管病变患者),将患者分为小血管病变组(886例,42.7%)和非小血管病变组(1191例,57.3%)。术后接受双联抗血小板药物(氯吡格雷和阿司匹林)治疗6个月,随后单用阿司匹林长期治疗,比较两组术后9个月定量冠状动脉造影(quantitive coronary angiography,QCA)复查结果及18个月临床随访主要不良心脏事件(major adverse cardiac events,MACE)、心性死亡和血栓事件的发生率。结果与非小血管组相比,小血管组女性(29.0%比24.5%)、高血压(59.9%比52.6%)、糖尿病(23.4%比19.6%)、既往有心肌梗死(14.0%比9.2%)的患者较多,平均年龄(61.9±10.6)岁比(59.6±11.4)岁。氯吡格雷用药时间两组(200.1±55.0)d比(197.4±55.0)d。小血管组患者病变较长(23.23±14.14)mm比(21.43±11.79)mm,人均支架置入数多(2.23±1.33)枚比(1.49±0.82)枚。术后9个月QCA结果显示,小血管组和非小血管组支架内晚期管腔丢失(0.20±0.38)mm比(0.21±0.42)mm和再狭窄率(3.9%比3.4%)。在合并有直径>2.75mm的非小血管病变的小血管组患者中,小血管和非小血管支架内晚期管腔丢失(0.23±0.40)mm比(0.31±0.60)mm和再狭窄率(4.4%比8.4%)。18个月临床随访结果表明,小血管组靶病变血运重建率(2.8%比1.2%)高于非小血管组,但两组MACE(3.9%比2.5%)、心性死亡(0.9%比1.3%)和支架内血栓(1.0%比0.8%)发生率。多因素Cox回归分析结果表明,小血管病变并非ExcelTM支架置入术后MACE发生的独立危险预测因素(OR=0.848,95%CI0.482~1.491,P=0.567)。结论 ExcelTM支架治疗冠状动脉小血管病变的长期疗效及安全性与非小血管病变相近,但还需随机对照临床研究进一步加以证实。

关键词(KeyWords)： 药物洗脱支架;冠状动脉疾病;血管成形术,经腔,经皮冠状动脉

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 路新磊,韩雅玲,王效增,荆全民,李毅,鄢高亮,李晶,徐波

参考文献(References)：

• [1]Fischman DL,Leon MB,Baim DS,et al.A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease.N Engl J Med,1994,331:496-501.
• [2]Betriu A,Masotti M,Serra A,et al.Randomized comparison of coronary stent implantation and balloon angioplasty in the treatment of de novo coronary artery lesions(START):a four-year follow-up.J Am Coll Cardiol,1999,34:1498-1506.
• [3]Akiyama T,Moussa I,Reimers B,et al.Angiographic and clinical outcome following coronary stenting of small vessels:a comparison with coronary stenting of large vessels.J Am Coll Cardiol,1998,32:1610-1618.
• [4]Cutlip DE,Baim DS,Ho KK,et al.Stent thrombosis in the modern era:a pooled analysis of multicenter coronary stent clinical trials.Circulation,2001,103:1967-1971.
• [5]Wykrzykowska JJ,Serruys PW,Onuma Y,et al.Impact of vessel size on angiographic and clinical outcomes of revascularization with biolimus-eluting stent with biodegradable polymer and sirolimus-eluting stent with durable polymer the LEADERS trial substudy.JACC Cardiovasc Interv,2009,2:861-870.
• [6]Togni M,Eber S,Widmer J,et al.Impact of vessel size on outcome after implantation of sirolimus-eluting and paclitaxel-eluting stents:a subgroup analysis of the SIRTAX trial.J AmColl Cardiol,2007,50:1123-1131.
• [7]Silber S,Albertsson P,Avilés FF,et al.Guidelines for percutaneous coronary interventions.The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology.Eur Heart J,2005,26:804-847.
• [8]Cutlip DE,Windecker,S Mehran R,et al.Clinical end points in coronary stent trials:a case for standardized definitions.Circulation,2007,115:2344-2351.
• [9]Jabara R,Gradman M,Chen JP,et al.Clinical and angiographic features of small vessel stenting in the drug-eluting stent era.Clin Cardiol,2009,32:E40-45.
• [10]Gao RL,Xu B,Lu SZ,et al.Safety and efficacy of the CYPHER select sirolimus-eluting stent in the"real world"——clinical and angiographic results from the China CYPHER select registry.Int J Cardiol,2008,125:339-346.
• [11]Ong AT,McFadden EP,Regar E,et al.Late angiographic stent thrombosis(LAST)events with drug-eluting stents.J Am Coll Cardiol,2005,45:2088-2092.
• [12]Grines CL,Bonow RO,Casey DE Jr,et al.Prevention of premature discontinuation of dual anti-platelet therapy in patients with coronary artery stents:a science advisory from the American Heart Association,American College of Cardiology,Society for Cardiovascular Angiography and Interventions,American College of Surgeons,and American Dental Association,with representation from the American College of Physicians.Circulation,2007,115:813-818.
• [13]Chevalier B,Silber S,Park SJ,et al.Randomized comparison of the Nobori Biolimus A9-eluting coronary stent with the Taxus Libertépaclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries:the NOBORI1trial——Phase2.Circ Cardiovasc Interv,2009,2:188-195.
• [14]Han Y,Jing Q,Xu B,et al.Safety and efficacy of biodegradable polymer-coated sirolimus-eluting stents in"real-world"practice:18-month clinical and9-month angiographic outcomes.JACC Cardiovasc Interv,2009,2:303-309.
• [15]Schampaert E,Cohen EA,Schlüter M,et al.The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries(C-SIRIUS).J Am Coll Cardiol,2004,43:1110-1115.
• [16]Schofer J,Schlüter M,Gershlick AH,et al.Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries:double-blind,randomised controlled trial(E-SIRIUS).Lancet,2003,362:1093-1099.